Liquid Biopsy-based Monitoring System for Relapse of HCC After Liver Transplantation: A Multi-center and Prospective Study

NCT03708705 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2018-10-19

No results posted yet for this study

Summary

This study aims to develop a novel, reliable, liquid biopsy-based biomarker system for relapse of HCC associated with hepatitis B after liver transplantation.

Conditions

Interventions

OTHER

Risk model of tumor relapse

High risk factor model of tumor relapse after liver transplantation

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-20
Primary Completion
2020-05-01
Completion
2020-07-01

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03708705 on ClinicalTrials.gov